'Sglt2 inhibitors' diaporamas de présentation

Sglt2 inhibitors - PowerPoint PPT Presentation

Endovigilance in Diabetes

Endovigilance in Diabetes

Endovigilance in Diabetes. Dr.Ganapathi.B Dept.Of Endocrinology St.Johns Medical College Bangalore. Introduction. Endocrine abnormalities in diabetes is not uncommon. Should be vigilant in diagnosing them in patients with diabetes.

★ ★ ★ ★ ★

1.96k views • 51 slides
Endovigilance in Diabetes

Endovigilance in Diabetes

Endovigilance in Diabetes. Dr.Ganapathi.B Dept.Of Endocrinology St.Johns Medical College Bangalore. Introduction. Endocrine abnormalities in diabetes is not uncommon. Should be vigilant in diagnosing them in patients with diabetes.

★ ★ ★ ★ ★

515 views • 51 slides
The Role of SGLT-2 Inhibitors in the Management of Patients with Type 2 Diabetes

The Role of SGLT-2 Inhibitors in the Management of Patients with Type 2 Diabetes

The Role of SGLT-2 Inhibitors in the Management of Patients with Type 2 Diabetes. Lawrence Blonde, MD Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes, and Metabolic Diseases Ochsner Medical Center, New Orleans, LA. Disclosures: Lawrence Blonde, MD.

★ ★ ★ ★ ★

849 views • 49 slides
Diabetes and Coronary Artery Disease

Diabetes and Coronary Artery Disease

Diabetes and Coronary Artery Disease. By Jean Molinary , DO. Screening for Diabetes in Adults. ADA: Risk based, or starting at the age of 45, then every 3 years if normal. Diabetes is Target-oriented :. Macrovascular complications: higher with DM. Remember Why We Treat.

★ ★ ★ ★ ★

489 views • 47 slides
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA. Goals. Diagnosed Diabetes, 1958-2010. Despite Increasing Prevalence, T2D Remains Undertreated. Limitations of Conventional Glucose-Lowering Agents. Limitations of Conventional Glucose-Lowering Agents (cont).

★ ★ ★ ★ ★

491 views • 31 slides
Top Tips in Evidence-Based Care for HFrEF

Top Tips in Evidence-Based Care for HFrEF

Top Tips in Evidence-Based Care for HFrEF. Typical Patient With HFrEF. Key Therapies in HFrEF: How Do They Work?. 2016 ESC HF Guidelines: Next...Add an MRA and ARNI. Principles for Successful Treatment for HF. Starting and Titrating Drug Therapies in HFrEF.

★ ★ ★ ★ ★

303 views • 29 slides
Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients. Part 4 of 4. Incorporating SGLT2 Inhibitors into Practice:. Updates from EASD Mark W. Stolar, MD Associate Professor Clinical Medicine, General Internal Medicine and Geriatrics Feinberg School of Medicine

★ ★ ★ ★ ★

283 views • 26 slides
JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes. Presented By: Rahul Patel, MS, PharmD. C andidate 2015 Dr. Sam Shimomura, Associate Dean, Western University of Health Sciences Date:09/25/2014. Disclosure. I, Rahul Patel, have no conflict of interest to disclose.

★ ★ ★ ★ ★

1.6k views • 22 slides
Adverse Health and Social Consequences Associated With Obesity

Adverse Health and Social Consequences Associated With Obesity

Adverse Health and Social Consequences Associated With Obesity. Goals and Targets for CV Risk Factors. CVOTs With GLP-1 RAs. CVOTs With SGLT2 Inhibitors. Mechanisms of Action of Liraglutide for Weight Loss. Renal Outcomes With Glucose-Lowering Agents. Abbreviations. Abbreviations (cont).

★ ★ ★ ★ ★

238 views • 8 slides
Sodium-glucose co-transporter 2 (SGLT2) Inhibitors: New Target for Type 2 Diabetes Mellitus (T2DM) Review

Sodium-glucose co-transporter 2 (SGLT2) Inhibitors: New Target for Type 2 Diabetes Mellitus (T2DM) Review

Knocking out type2 diabetes by new insulin independent renal glucose transporters as targets, reducing the side effects related to high rise in glucose levels is a more efficient way to manage diabetes. Sodium-glucose co-transporter 2 (SGLT2) inhibitors block reabsorption of glucose back into the blood and stimulate secretion in urine in a way controlling blood glucose levels. Areas discussed: We emphasize in this review an overview of type 2 diabetes. New insulin independent targets, SGLT family inhibitors and their mechanism of action are briefly discussed. Molecular modeling studies carried out for new analogues of SGLT2 were indicated and also about current marketed SGLT drugs their safety issues are briefly outlined. Conclusion: SGLT2 inhibitors are very promising drugs for near future, where insulin sensitization is a problem. A combination of drugs related to insulin dependent pathway and also independent pathway like SGLT2/SGLT1 drugs will be more effective in glycemic control with lesser side effects.

★ ★ ★ ★ ★

65 views • 5 slides

View Sglt2 inhibitors PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Sglt2 inhibitors PowerPoint presentations. You can view or download Sglt2 inhibitors presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.